The FDA has extended the deadline to review Orca-T for the treatment of myelodsyplastic syndromes and acute leukemias with a ...
In an interview with Targeted Oncology, Pavlos Msaouel, MD, PhD, at The University of Texas MD Anderson Cancer Center ...
Dr. Nooka presents a comprehensive treatment algorithm for 100 patients with relapsed multiple myeloma, providing clear ...
Victoria Rizk, MD, explores genomic assays to refine adjuvant therapy and capture clinical real-world evidence in breast ...
CB-011, an allogeneic CAR T product, received RMAT designation as treatment for multiple myeloma based on strong dose ...
The phase 3 ATOMIC trial is changing the way we treat stage III dMMR colon cancer. In this video, Dr. Sinicrope breaks down the landmark findings, and explains why this trial is now considered ...
Datopotamab deruxtecan showed a 5.0-month OS improvement versus chemotherapy in first-line unresectable/metastatic TNBC ...
Dr. Nooka presents a case-based approach to treatment selection using a 50-year-old woman with relapsed/refractory multiple myeloma who progressed after 15 months on lenalidomide maintenance following ...
The conversation highlights how AI is redefining what it means to be a medical expert. Pattern Recognition: Modern expertise ...
In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate ...
With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Dr Ferris addresses ...
The FDA has granted a priority review to a new drug application (NDA) for lirafugratinib, a highly selective oral FGFR2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results